HC Wainwright Issues Negative Outlook for Brainsway Earnings

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – HC Wainwright lowered their FY2026 earnings per share estimates for shares of Brainsway in a research report issued on Monday, August 31st. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.38 for the year, down from their previous estimate of $0.42. HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Brainsway’s current full-year earnings is $0.34 per share.

Several other equities research analysts also recently weighed in on BWAY. Weiss Ratings downgraded shares of Brainsway from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, August 19th. LADENBURG THALM/SH SH boosted their target price on Brainsway from $18.00 to $18.80 and gave the company a “buy” rating in a research report on Thursday, August 13th. BTIG Research raised their price objective on Brainsway from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Wall Street Zen upgraded Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 2nd. Finally, Zacks Research cut Brainsway from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Brainsway currently has a consensus rating of “Moderate Buy” and an average price target of $18.20.

Brainsway Stock Down 1.7%

NASDAQ:BWAY opened at $14.27 on Wednesday. Brainsway has a twelve month low of $7.14 and a twelve month high of $17.40. The company has a fifty day moving average of $15.21 and a 200-day moving average of $14.65. The firm has a market capitalization of $573.50 million, a P/E ratio of 32.43 and a beta of 1.24.

Brainsway (NASDAQ:BWAY) last announced its earnings results on Wednesday, August 12th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. Brainsway had a return on equity of 12.74% and a net margin of 15.65%.The company had revenue of $17.11 million for the quarter, compared to analyst estimates of $16.54 million.

Institutional Investors Weigh In On Brainsway

Several hedge funds and other institutional investors have recently modified their holdings of BWAY. Masters Capital Management LLC increased its holdings in Brainsway by 65.0% during the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock worth $21,928,000 after acquiring an additional 650,000 shares during the period. Renaissance Technologies LLC grew its position in shares of Brainsway by 87.2% during the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock valued at $6,890,000 after purchasing an additional 241,560 shares in the last quarter. Sei Investments Co. grew its position in shares of Brainsway by 262.5% during the 1st quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock valued at $3,009,000 after purchasing an additional 163,925 shares in the last quarter. Y.D. More Investments Ltd increased its holdings in shares of Brainsway by 136.6% in the first quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock worth $3,615,000 after purchasing an additional 157,042 shares during the period. Finally, ARK Investment Management LLC purchased a new stake in shares of Brainsway in the fourth quarter worth $2,422,000. 30.11% of the stock is currently owned by institutional investors.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.